Phillip Scheinberg

List of Publications by Year
in descending order

127	10,162	57719	34964
papers	citations	44 h-index	98 g-index

129	129	129	11425
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Current concepts in the pathophysiology and treatment of aplastic anemia. Blood, 2006, 108, 2509-2519.	0.6	766
2	Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science, 2014, 345, 1623-1627.	6.0	745
3	Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood, 2008, 112, 2826-2835.	0.6	562
4	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. New England Journal of Medicine, 2015, 373, 35-47.	13.9	508
5	Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. New England Journal of Medicine, 2012, 367, 11-19.	13.9	454
6	Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. New England Journal of Medicine, 2011, 365, 430-438.	13.9	415
7	Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. New England Journal of Medicine, 2017, 376, 1540-1550.	13.9	393
8	How I treat acquired aplastic anemia. Blood, 2012, 120, 1185-1196.	0.6	351
9	Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood, 2014, 123, 1818-1825.	0.6	336
10	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T _{regs}) with Minimal Loss of in Vivo Functional Activity. Science Translational Medicine, 2011, 3, 83ra41.	5.8	326
11	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, The, 2021, 372, n84.	3.0	309
12	Danazol Treatment for Telomere Diseases. New England Journal of Medicine, 2016, 374, 1922-1931.	13.9	300
13	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology, 2019, 37, 1188-1199.	0.8	277
14	Aplastic anemia. Current Opinion in Hematology, 2008, 15, 162-168.	1.2	223
15	Immunisation with BCG and recombinant MVA85A induces longâ€lasting, polyfunctional Mycobacterium tuberculosisâ€specific CD4⁺ memory T lymphocyte populations. European Journal of Immunology, 2007, 37, 3089-3100.	1.6	206
16	Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. British Journal of Haematology, 2009, 144, 206-216.	1.2	181
17	Association of Telomere Length of Peripheral Blood Leukocytes With Hematopoietic Relapse, Malignant Transformation, and Survival in Severe Aplastic Anemia. JAMA - Journal of the American Medical Association, 2010, 304, 1358.	3.8	173
18	Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. British Journal of Haematology, 2006, 133, 622-627.	1.2	149

#	Article	IF	Citations
19	Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood, 2010, 116, 4175-4184.	0.6	149
20	Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica, 2009, 94, 348-354.	1.7	147
21	Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. British Journal of Haematology, 2006, 133, 606-611.	1.2	143
22	Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Frontiers in Immunology, 2019, 10, 1157.	2.2	133
23	Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood, 2007, 109, 3219-3224.	0.6	125
24	TCR Î²-Chain Sharing in Human CD8+ T Cell Responses to Cytomegalovirus and EBV. Journal of Immunology, 2008, 181, 7853-7862.	0.4	124
25	Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions. Journal of Clinical Oncology, 2010, 28, 5166-5173.	0.8	119
26	Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica, 2011, 96, 602-606.	1.7	113
27	Long-Term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Antithymocyte Globulin and Cyclosporine. Journal of Pediatrics, 2008, 153, 814-819.e1.	0.9	111
28	Chemokine Receptor Ccr1 Drives Neutrophil-Mediated Kidney Immunopathology and Mortality in Invasive Candidiasis. PLoS Pathogens, 2012, 8, e1002865.	2.1	102
29	Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two Decades. Clinical Infectious Diseases, 2011, 52, 726-735.	2.9	101
30	Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood, 2012, 119, 345-354.	0.6	98
31	Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine. Haematologica, 2010, 95, 1075-1080.	1.7	95
32	Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia, 2012, 26, 700-707.	3.3	95
33	CMV-specific T cells generated from naÃ¯ve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine, 2015, 7, 285ra63.	5.8	93
34	Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica, 2009, 94, 1661-1668.	1.7	84
35	The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood, 2009, 114, 5071-5080.	0.6	82
36	T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood, 2011, 117, 2691-2699.	0.6	77

#	Article	IF	Citations
37	Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood, 2019, 133, 2575-2585.	0.6	77
38	Infections in Patients With Aplastic Anemia. Seminars in Hematology, 2009, 46, 269-276.	1.8	73
39	Probioticâ€associated highâ€titer antiâ€B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion, 2009, 49, 1845-1849.	0.8	71
40	Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology American Society of Hematology Education Program, 2012, 2012, 292-300.	0.9	64
41	Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Experimental Hematology, 2008, 36, 1616-1624.	0.2	57
42	High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood, 2009, 113, 2238-2244.	0.6	57
43	Activity of eltrombopag in severe aplastic anemia. Blood Advances, 2018, 2, 3054-3062.	2.5	50
44	Techniques to improve the direct ex vivo detection of low frequency antigenâ€specific CD8⁺ T cells with peptideâ€major histocompatibility complex class I tetramers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1001-1009.	1.1	49
45	Aplastic Anemia: What Have We Learned From Animal Models and From the Clinic. Seminars in Hematology, 2013, 50, 156-164.	1.8	45
46	Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leukemia Research, 2012, 36, 982-989.	0.4	43
47	Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. American Journal of Hematology, 2014, 89, 571-574.	2.0	43
48	Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood, 2010, 116, 4546-4559.	0.6	41
49	Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology American Society of Hematology Education Program, 2012, 2012, 292-300.	0.9	41
50	Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood, 2014, 124, 2820-2823.	0.6	39
51	Clonotype and Repertoire Changes Drive the Functional Improvement of HIV-Specific CD8 T Cell Populations under Conditions of Limited Antigenic Stimulation. Journal of Immunology, 2012, 188, 1156-1167.	0.4	38
52	In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica, 2014, 99, 1433-1440.	1.7	38
53	Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2012, 10, 1616-1623.	1.9	36
54	Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation. Haematologica, 2012, 97, 867-873.	1.7	34

#	Article	IF	Citations
55	Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Lancet Haematology,the, 2016, 3, e22-e29.	2.2	33
56	Detection of low avidity CD8+ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. Journal of Immunological Methods, 2008, 338, 31-39.	0.6	32
57	A plasma microRNA signature as a biomarker for acquired aplastic anemia. Haematologica, 2017, 102, 69-78.	1.7	32
58	Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biology of Blood and Marrow Transplantation, 2011, 17, 291-299.	2.0	31
59	Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries. British Journal of Haematology, 2021, 194, 954-969.	1.2	30
60	Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica, 2010, 95, 382-387.	1.7	25
61	Alloreactivity Across HLA Barriers Is Mediated by Both NaÃ¯ve and Antigen-Experienced T Cells. Biology of Blood and Marrow Transplantation, 2011, 17, 800-809.	2.0	24
62	Activity of eltrombopag in severe aplastic anemia. Hematology American Society of Hematology Education Program, 2018, 2018, 450-456.	0.9	23
63	Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3â¯ T cells in complete DiGeorge anomaly. Clinical and Experimental Immunology, 2013, 173, 140-149.	1.1	22
64	The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements. Journal of Immunological Methods, 2007, 321, 107-120.	0.6	21
65	Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. American Journal of Hematology, 2014, 89, 467-469.	2.0	21
66	Long-Term Outcome of Fludarabine-Based Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Debilitating Paroxysmal Nocturnal Hemoglobinuria. Biology of Blood and Marrow Transplantation, 2014, 20, 1435-1439.	2.0	20
67	Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: Implications for graft engineering. Experimental Hematology, 2006, 34, 788-795.	0.2	16
68	Hematopoietic stem cell transplantation for cutaneous Tâ€cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil. Journal of Dermatology, 2016, 43, 638-642.	0.6	16
69	Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates. Blood, 2015, 126, LBA-2-LBA-2.	0.6	16
70	Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study. Annals of Hematology, 2018, 97, 2039-2046.	0.8	15
71	Prognostic value of telomere attrition in patients with aplastic anemia. International Journal of Hematology, 2013, 97, 553-557.	0.7	14
72	Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia. Haematologica, 2015, 100, e345-e347.	1.7	14

#	Article	IF	Citations
73	Recent Advances and Long-Term Results of Medical Treatment of Acquired Aplastic Anemia. Hematology/Oncology Clinics of North America, 2018, 32, 609-618.	0.9	14
74	Brief Communication: Successful Treatment of Pure Red-Cell Aplasia with an Antiâ€“Interleukin-2 Receptor Antibody (Daclizumab). Annals of Internal Medicine, 2006, 144, 181.	2.0	13
75	Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. Clinical Rheumatology, 2014, 33, 1347-1349.	1.0	12
76	Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling. Blood, 2017, 130, 777-777.	0.6	12
77	Novel therapeutic choices in immune aplastic anemia. F1000Research, 2020, 9, 1118.	0.8	11
78	Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia. Annals of Hematology, 2017, 96, 1907-1914.	0.8	10
79	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood, 2018, 132, 445-445.	0.6	9
80	Immunosuppressive therapy in severe aplastic anemia. Seminars in Hematology, 2022, 59, 21-29.	1.8	9
81	Severe Menorrhagia Associated With Thrombocytopenia. Obstetrics and Gynecology, 2007, 110, 913-917.	1.2	8
82	Regulatory T-cell depletion does not prevent emergence of new CD25+ FOXP3+ lymphocytes after antigen stimulation in culture. Cytotherapy, 2008, 10, 152-164.	0.3	8
83	Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients. Transfusion, 2007, 47, 1250-1253.	0.8	7
84	Apparent hemolysis following intravenous antithymocyte globulin treatment in a patient with marrow failure and a paroxysmal nocturnal hemoglobinuria clone. Transfusion, 2006, 46, 1244-1247.	0.8	6
85	Response: EBV reactivation in the immunosuppressed: to treat or not to treat?. Blood, 2008, 111, 1739-1740.	0.6	6
86	A New Standard Immunosuppression Regimen in Severe Aplastic Anemia. New England Journal of Medicine, 2022, 386, 89-90.	13.9	6
87	Stem-cell transplantation for autoimmune diseases. Cytotherapy, 2003, 5, 243-251.	0.3	5
88	Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A. Jornal De Pediatria, 2014, 90, 523-527.	0.9	5
89	Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Advances, 2019, 3, 980-983.	2.5	5
90	Stem cell stimulation continues to pay off in aplastic anaemia. Lancet Haematology,the, 2019, 6, e543-e544.	2.2	5

#	Article	IF	Citations
91	Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia. British Journal of Haematology, 2021, 193, 410-414.	1.2	5
92	Peptide-Major Histocompatibility Complex Class I Tetramers with Enhanced Coreceptor Binding Properties Enable Visualization of Low Avidity Leukemia-Associated Antigen-Specific CD8+ T Cells.. Blood, 2007, 110, 1343-1343.	0.6	4
93	Monosomy 7 Detected by FISH at Disease Presentation Is a Marker for Non-Response to Immunosuppression.. Blood, 2007, 110, 1697-1697.	0.6	3
94	Cyclosporine Taper Does Not Prevent Relapse in Severe Aplastic Anemia. Blood, 2011, 118, 2406-2406.	0.6	3
95	A Pilot Study Of Rituximab In Patients With Moderate Aplastic Anemia, Diamond-Blackfan Anemia and Pure Red Cell Aplasia. Blood, 2013, 122, 2479-2479.	0.6	3
96	Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 229-229.	0.6	2
97	Circulating Cytokine Profiles of Patients with Acquired Aplastic Anemia and Myelodysplastic Syndrome. Blood, 2008, 112, 1038-1038.	0.6	2
98	Eltrombopag Can Stimulate Trilineage Hematopoiesis with Transfusion Independence in Patients with Refractory Severe Aplastic Anemia: Results From a Phase II Trial. Blood, 2011, 118, 54-54.	0.6	2
99	Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome. Blood, 2013, 122, 593-593.	0.6	2
100	Posterior Segment Ophthalmic Complications of Aplastic Anemia. Ophthalmic Surgery, Lasers and Imaging, 2010, 41 Online, .	0.5	2
101	Aplastic anemia. Current Opinion in Internal Medicine, 2008, 7, 338-344.	1.5	1
102	Current management of severe acquired aplastic anemia. Einstein (Sao Paulo, Brazil), 2011, 9, 229-235.	0.3	1
103	Mesenchymal stromal cells: filling the void of immunosuppressive therapy in aplastic anemia?. Cytotherapy, 2013, 15, 751-752.	0.3	1
104	Why do Tregs suddenly disappear in aplastic anemia?. Blood, 2020, 136, 779-780.	0.6	1
105	Clinical and Genetic Heterogeneity of Telomere Diseases.. Blood, 2012, 120, 2373-2373.	0.6	1
106	Myeloid Neoplasm Gene Somatic Mutations in Patients with Severe Aplastic Anemia Treated with Eltrombopag and Standard Immunosuppression. Blood, 2016, 128, 727-727.	0.6	1
107	Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size. Blood, 2013, 122, 3705-3705.	0.6	1
108	A Plasma microRNA Signature As a Biomarker for Acquired Aplastic Anemia. Blood, 2016, 128, 728-728.	0.6	1

#	Article	IF	Citations
109	Update in Internal Medicine. Archives of Medical Research, 2000, 31, 329-352.	1.5	0
110	Immunosuppression or immunostimulation for aplastic anemia? A blast from the past. Cytotherapy, 2010, 12, 574-575.	0.3	0
111	Reply to R. Tibes et al. Journal of Clinical Oncology, 2011, 29, 4842-4843.	0.8	0
112	Thymus Transplantation Restores the Repertoire of Foxp3+ T Cells in Complete DiGeorge Anomaly. Journal of Allergy and Clinical Immunology, 2013, 131, AB196.	1.5	0
113	Extending the Option of CMV-Specific T Cells from the CMV-Seronegative Donor. Biology of Blood and Marrow Transplantation, 2014, 20, S131.	2.0	0
114	Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A. Jornal De Pediatria (VersÃ£o Em PortuguÃªs), 2014, 90, 523-527.	0.2	0
115	Answer to "Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia". Haematologica, 2015, 100, e213-e213.	1.7	0
116	CMVpp65-Specific T Cells Generated from NaÃ¯ve T Cell Populations Recognize Atypical but Not Canonical Epitopes and May Be Protective In Vivo. Biology of Blood and Marrow Transplantation, 2015, 21, S51-S52.	2.0	0
117	How deep can you go into Tregs?. Blood, 2016, 128, 1158-1159.	0.6	0
118	Developing role of eltrombopag in the treatment of aplastic anemia. Expert Opinion on Orphan Drugs, 2018, 6, 231-235.	0.5	0
119	Treatment of Severe Aplastic Anemia with Combined Immunosuppression: Antithymocyte Globulin (ATG), Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF).. Blood, 2005, 106, 3758-3758.	0.6	0
120	Subclinical EBV and CMV Reactivations Commonly Occur Following Antibody-Based Immunosuppressive Regimens for Patients with Severe Aplastic Anemia.. Blood, 2005, 106, 1428-1428.	0.6	0
121	High Avidity Leukemia-Associated Antigen-Specific CD8+ T Cells Preferentially Localize to the Bone Marrow in Patients with Myeloid Malignancies.. Blood, 2007, 110, 2763-2763.	0.6	0
122	Plasma Cytokines Associated with Low Platelet Counts in Aplastic Anemia and Immune Thrombocytopenia.. Blood, 2009, 114, 1317-1317.	0.6	0
123	Different In Vivo Effects of Horse and Rabbit Antithymocyte Globulin in Patients with Severe Aplastic Anemia. Blood, 2011, 118, 2399-2399.	0.6	0
124	HLA and Aplastic Anemia: associations In Large Brazilian Cohorts. Blood, 2013, 122, 1237-1237.	0.6	0
125	The Interferon Gamma Gene Polymorphism In Acquired Aplastic Anemia and Its Association With HLA. Blood, 2013, 122, 1236-1236.	0.6	0
126	AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2014, 32, TPS8614-TPS8614.	0.8	0

#	Article	IF	Citations
127	Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL). Blood, 2018, 132, 5554-5554.	0.6	0